# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of ...
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of...
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy rating and ann...
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.